Abstract:BACKGROUND:To determine the potential value of serum tumor markers in predicting pCR (pathological complete response) during neoadjuvant chemotherapy. MATERIALS AND METHODS:We retrospectively monitored the pro-, mid-, and post- neoadjuvant treatment serum tumor marker concentrations in patients with locally advanced breast cancer (stage II-III) who accepted pre-surgical chemotherapy or chemotherapy in combination with targeted therapy at Fudan University Shanghai Cancer Center between September 2011 and January 2014 and investigated the association of serum tumor marker levels with therapeutic effect. Core needle biopsy samples were assessed using immunohistochemistry (IHC) prior to neoadjuvant treatment to determine hormone receptor, human epidermal growth factor receptor 2(HER2), and proliferation index Ki67 values. In our study, therapeutic response was evaluated by pCR, defined as the disappearance of all invasive cancer cells from excised tissue (including primary lesion and axillary lymph nodes) after completion of chemotherapy. Analysis of variance of repeated measures and receiver operating characteristic (ROC) curves were employed for statistical analysis of the data. RESULTS:A total of 348 patients were recruited in our study after excluding patients with incomplete clinical information. Of these, 106 patients were observed to have acquired pCR status after treatment completion, accounting for approximately 30.5% of study individuals. In addition, 147patients were determined to be Her-2 positive, among whom the pCR rate was 45.6% (69 patients). General linear model analysis (repeated measures analysis of variance) showed that the concentration of cancer antigen (CA) 15-3 increased after neoadjuvant chemotherapy in both pCR and non-pCR groups, and that there were significant differences between the two groups (P=0.008). The areas under the ROC curves (AUCs) of pre-, mid-, and post-treatment CA15-3 concentrations demonstrated low-level predictive value (AUC=0.594, 0.644, 0.621, respectively). No significant differences in carcinoembryonic antigen (CEA) or CA12-5 serum levels were observed between the pCR and non-pCR groups (P=0.196 and 0.693, respectively). No efficient AUC of CEA or CA12-5 concentrations were observed to predict patient response toward neoadjuvant treatment (both less than 0.7), nor were differences between the two groups observed at different time points. We then analyzed the Her-2 positive subset of our cohort. Significant differences in CEA concentrations were identified between the pCR and non-pCR groups (P=0.039), but not in CA15-3 or CA12-5 levels (p=0.092 and 0.89, respectively). None of the ROC curves showed underlying prognostic value, as the AUCs of these three markers were less than 0.7. The ROC-AUCs for the CA12-5 concentrations of inter-and post-neoadjuvant chemotherapy in the estrogen receptor negative HER2 positive subgroup were 0.735 and 0.767, respectively. However, the specificity and sensitivity values were at odds with each other which meant that improving either the sensitivity or specificity would impair the efficiency of the other. CONCLUSIONS:Serum tumor markers CA15-3, CA12-5, and CEA might have little clinical significance in predicting neoadjuvant treatment response in locally advanced breast cancer.

Effect of neoadjuvant chemotherapy on expression of biological markers in breast cancer

Effects of Core Needle Biopsy and Subsequent Neoadjuvant Chemotherapy on Molecular Alterations and Outcome in Breast Cancer

The Influence of Preoperative Biopsy on the Surgical Method in Breast Cancer Patients: a Single-Center Experience of 3,966 Cases in China

Morphologic changes of breast carcinoma after neoadjuvant therapy and its differential diagnosis

Effect of neoadjuvant chemotherapy on histopathology and immunohistochemistry in breast cancer

[Effect of Neoadjuvant Chemotherapy on Estrogen and Progesterone Receptors and P53 and CerbB-2 in Breast Cancer].

Comparison of core needle biopsy and surgical specimens for accurate evaluation of hormonal receptors status and molecular subtypes of breast cancer

[The Effect of Neoadjuvant Chemotherapy on Estrogen and Progesterone Receptor Expression in Breast Carcinoma].

Influence of Neoadjuvant Chemotherapy on ER,PR,C-erbB-2,Ki-67 Expressions of Breast Cancer Patients

Expression of ER, PR, HER-2, Ki-67 Before and after Neoadjuvant Chemotherapy and the Relation Between Their Expression and the Curative Effects of Neoadjuvant Chemotherapy in Breast Cancer

Clinical study on preoperative core needle biopsy of breast cancer and detection of ER、PR、C-erbB-2、Ki-67

Clinical research of utilizing Ki67 in predicting the effect of neoadjuvant chemotherapy on breast cancer

Impact of preoperative core needle biopsy on prognosis of breast cancer patients

Effect of neoadjuvant chemotherapy on histologic grade and expression of biological markers in breast cancer]

Influence of Neoadjuvant Chemotherapy of Different Regimen on Expression of Hormonal Receptors in Breast Cancer

Relationship of peripheral blood circulating tumor cells with therapeutic effect of neoadjuvant chemotherapy in breast cancer:report of 70 cases

Clinical observation of neoadjuvant chemotherapy on 86 breast cancer patients

Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer

Correlation of biomarker expression and therapeutic efficiency in locally advanced breast cancer after neoadjuvant chemotherapy

Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.

Alteration of Biomarker HER-2 Between Pre-and Post-neoadjuvant Chemotherapy in Breast Cancer Patients